Section Arrow
ALVO.NASDAQ
- Alvotech
Quotes are at least 15-min delayed:2026/05/13 07:15 EDT
Pre Market
Last
 3.54
-0.01 (-0.28%)
Bid
3.38
Ask
4
High 3.54 
Low 3.54 
Volume 83 
Regular Hours (Closed)
Last
 3.55
-0.04 (-1.11%)
Day High 
3.5929 
Prev. Close
3.59 
1-M High
3.78 
Volume 
377.37K 
Bid
3.38
Ask
4
Day Low
3.375 
Open
3.59 
1-M Low
3.17 
Market Cap 
1.12B 
Currency 美元 
P/E 35.5 
%Yield -- 
10-SMA 3.43 
20-SMA 3.47 
50-SMA 3.56 
52-W High 11.85 
52-W Low 3.03 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.10/1.07
Enterprise Value
2.52B
Balance Sheet
Book Value Per Share
-0.91
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
586.32M
Operating Revenue Per Share
0.20
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
HIMSHims & Hers Health25.03-4.11-14.10%57.14PE
Pre Market 24.87 -0.16 -0.64%
ZTSZOETIS76.94+0.27+0.35%12.61PE
Pre Market 77.15 +0.21 +0.27%
CPHIChina Pharma Holdings Inc0.8927+0.35855+67.13%-- 
Pre Market 0.8318 -0.0609 -6.82%
VTRSViatris17.17+0.25+1.48%-- 
Pre Market 17.29 +0.12 +0.70%
ELANElanco Animal Health21.43-0.29-1.34%-- 
Pre Market 22.9 +1.47 +6.86%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.